Clincosm LogoSign in Get a demo

Maternal Serum Alpha-fetoprotein Level May Predict the Presence of Morbid Adherent Placenta

Sponsor
rasha medhat abdul-hady (Other)
Overall Status
Unknown status
CT.gov ID
NCT04082507
Collaborator
(none)
150
Enrollment
1
Location
31.9
Anticipated Duration (Months)
4.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The aim of the study is to compare between alpha-fetoproteine as a biological marker and between ultrasound and Doppler in prediction of morbid adherent placenta.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Serum alpha-fetoproteine

Detailed Description

in pregnant women withe previous cesarean section, placenta previa and ultrasonographic finding of an abnormally adherent placenta dose maternal serum alpha-fetoprotein predict prenataly the presence of morbid adherent placenta accurately?

Study Design

Study Type:
Observational
Anticipated Enrollment :
150 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Alpha-fetoprotein as a Biochemical Marker in Prediction of Placenta Acreta Increta Percreta
Actual Study Start Date :
Jan 1, 2017
Anticipated Primary Completion Date :
Aug 30, 2019
Anticipated Study Completion Date :
Aug 30, 2019

Arms and Interventions

Arm Intervention/Treatment
Non_adherent plcenta

placenta separated within 15 minutes after delivery of fetus
Adherent placenta

placenta dosenot separated within 15 minutes after delivery of fetus

Diagnostic Test: Serum alpha-fetoproteine
Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan .
Other Names:
  • 2D Ultrasound
  • 3D power doppler with MS US

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Maternal serum alpha-fetoprotein [From 28weeks to 37 weeks]

      ng/ml or MOM(Multiple of the median)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 39 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • pregnant women with history of scarred uterus

    • plcenta previa covering the scar of previous caesarean section as diagnosed by 2DU/S

    • Gestational age from 28wks to full term

    Exclusion Criteria:

    • pregnant women with fetus with congenital anomalies

    • pregnant women with ovarian swelling

    • pregnant women with medical disease

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ain shams university maternity hospital Cairo Egypt

    Sponsors and Collaborators

    • rasha medhat abdul-hady

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    rasha medhat abdul-hady, Lecturer of obstetrics and gynecology, Ain Shams University
    ClinicalTrials.gov Identifier:
    NCT04082507
    Other Study ID Numbers:
    • AFP_AP
    First Posted:
    Sep 9, 2019
    Last Update Posted:
    Sep 9, 2019
    Last Verified:
    Sep 1, 2019
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Placenta Accreta

    Study Results

    No Results Posted as of Sep 9, 2019